Clomipramine: Difference between revisions

From Glioblastoma Treatments
Jump to navigationJump to search
No edit summary
No edit summary
Line 18: Line 18:
|toxicity_level=
|toxicity_level=
|toxicity_level=
|toxicity_level=
|toxicity_level=2
}}
}}

Revision as of 08:10, 27 March 2024

Property Information
Drug Name Clomipramine (Chlorimipramine)
FDA Approval Yes (for depression and obsessive-compulsive neuroses)
Used for High-grade gliomas, including glioblastoma multiforme (GBM)
Clinical Trial Phase Initial findings reported; further research needed
Clinical Trial Explanation Not specified
Common Side Effects Known for its general tolerability; specific studies on glioma treatment might reveal more details
OS without Median survival with traditional treatments like BCNU alone reported at 11 months
OS with When combined with chloroquine, median survival extended to 25-33 months according to early studies
PFS without Not specified
PFS with Improvement in PFS-6 when combined with traditional chemotherapy agents
Usefulness Rating 3
Usefulness Explanation Not specified
Toxicity Level Not specified
Toxicity Explanation Not specified

Notes: Clomipramine, an antidepressant, has shown promise in treating high-grade gliomas by selectively depressing mitochondrial function in glioma cells, leading to apoptosis. Initial studies suggest potential efficacy in extending survival when combined with chemotherapy, though further detailed research is essential to validate these findings and explore mechanisms like autophagy inhibition.


From Ben Williams Book: Not specified

Loading comments...

|toxicity_level= |toxicity_level= |toxicity_level= |toxicity_level= |toxicity_level=2 }}